{"entity":{"type":"insider","cik":"0001860609","url":"/insider/0001860609","json_url":"/insider/0001860609.json","name":"Patel Sushil","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":22,"n_filings":13,"first":"2022-05-18","last":"2026-08-12","span_basis":"filed_date"},"name_variants":[{"name":"Patel Sushil","source":"filing","n_filings":13,"first_seen":"2022-05-18","last_seen":"2026-08-12"}],"transactions":[{"id":9224054,"accession":"0001104659-26-095012","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-095012","line_url":"/filing/0001104659-26-095012#line-1","is_derivative":false,"issuer_cik":"0001737953","issuer_name":"Replimune Group, Inc.","issuer_ticker":"REPL","issuer_name_source":null,"issuer_url":"/issuer/0001737953","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":39341.0,"shares_display":"39,341","price_per_share":12.97,"price_display":"12.97","price_state":"stated","total_value":510252.77,"total_display":"510,252.77","total_whole":"510,253","shares_owned_after":708151.0,"shares_owned_after_display":"708,151","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-10","filed_date":"2026-08-12","scope":"insider"},{"id":6039712,"accession":"0001610717-26-000311","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001610717-26-000311","line_url":"/filing/0001610717-26-000311","is_derivative":false,"issuer_cik":"0001628171","issuer_name":"Revolution Medicines, Inc.","issuer_ticker":"RVMD","issuer_name_source":null,"issuer_url":"/issuer/0001628171","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5580.0,"shares_display":"5,580","price_per_share":187.9869707168459,"price_display":"187.99","price_state":"stated","total_value":1048967.2966,"total_display":"1,048,967.30","total_whole":"1,048,967","shares_owned_after":24936.0,"shares_owned_after_display":"24,936","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-29","filed_date":"2026-07-01","scope":"insider","n_lines":9},{"id":5883020,"accession":"0001104659-26-064519","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-26-064519","line_url":"/filing/0001104659-26-064519#line-1","is_derivative":false,"issuer_cik":"0001737953","issuer_name":"Replimune Group, Inc.","issuer_ticker":"REPL","issuer_name_source":null,"issuer_url":"/issuer/0001737953","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37324.0,"shares_display":"37,324","price_per_share":5.08,"price_display":"5.08","price_state":"stated","total_value":189605.92,"total_display":"189,605.92","total_whole":"189,606","shares_owned_after":747492.0,"shares_owned_after_display":"747,492","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-18","filed_date":"2026-05-20","scope":"insider"},{"id":4064619,"accession":"0001104659-25-118483","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-118483","line_url":"/filing/0001104659-25-118483#line-1","is_derivative":false,"issuer_cik":"0001737953","issuer_name":"Replimune Group, Inc.","issuer_ticker":"REPL","issuer_name_source":null,"issuer_url":"/issuer/0001737953","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":11.13,"price_display":"11.13","price_state":"stated","total_value":111300.0,"total_display":"111,300.00","total_whole":"111,300","shares_owned_after":333576.0,"shares_owned_after_display":"333,576","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-02","filed_date":"2025-12-04","scope":"insider"},{"id":4168189,"accession":"0001104659-25-052143","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-25-052143","line_url":"/filing/0001104659-25-052143#line-1","is_derivative":false,"issuer_cik":"0001737953","issuer_name":"Replimune Group, Inc.","issuer_ticker":"REPL","issuer_name_source":null,"issuer_url":"/issuer/0001737953","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25105.0,"shares_display":"25,105","price_per_share":8.06,"price_display":"8.06","price_state":"stated","total_value":202346.3,"total_display":"202,346.30","total_whole":"202,346","shares_owned_after":343576.0,"shares_owned_after_display":"343,576","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-20","filed_date":"2025-05-22","scope":"insider"},{"id":2171597,"accession":"0001104659-24-129864","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-129864","line_url":"/filing/0001104659-24-129864#line-1","is_derivative":false,"issuer_cik":"0001737953","issuer_name":"Replimune Group, Inc.","issuer_ticker":"REPL","issuer_name_source":null,"issuer_url":"/issuer/0001737953","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":12.42,"price_display":"12.42","price_state":"stated","total_value":124200.0,"total_display":"124,200.00","total_whole":"124,200","shares_owned_after":202014.0,"shares_owned_after_display":"202,014","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-16","filed_date":"2024-12-18","scope":"insider"},{"id":3057693,"accession":"0001610717-24-000516","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001610717-24-000516","line_url":"/filing/0001610717-24-000516#line-2","is_derivative":false,"issuer_cik":"0001628171","issuer_name":"Revolution Medicines, Inc.","issuer_ticker":"RVMD","issuer_name_source":null,"issuer_url":"/issuer/0001628171","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":54.1429,"price_display":"54.14","price_state":"stated","total_value":270714.5,"total_display":"270,714.50","total_whole":"270,715","shares_owned_after":19948.0,"shares_owned_after_display":"19,948","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-31","filed_date":"2024-11-04","scope":"insider"},{"id":3186395,"accession":"0001610717-24-000394","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001610717-24-000394","line_url":"/filing/0001610717-24-000394#line-2","is_derivative":false,"issuer_cik":"0001628171","issuer_name":"Revolution Medicines, Inc.","issuer_ticker":"RVMD","issuer_name_source":null,"issuer_url":"/issuer/0001628171","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2155.0,"shares_display":"2,155","price_per_share":44.0,"price_display":"44.00","price_state":"stated","total_value":94820.0,"total_display":"94,820.00","total_whole":"94,820","shares_owned_after":19948.0,"shares_owned_after_display":"19,948","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-09","filed_date":"2024-07-10","scope":"insider"},{"id":2599772,"accession":"0001104659-24-063559","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-24-063559","line_url":"/filing/0001104659-24-063559#line-1","is_derivative":false,"issuer_cik":"0001737953","issuer_name":"Replimune Group, Inc.","issuer_ticker":"REPL","issuer_name_source":null,"issuer_url":"/issuer/0001737953","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20194.0,"shares_display":"20,194","price_per_share":6.47,"price_display":"6.47","price_state":"stated","total_value":130655.18,"total_display":"130,655.18","total_whole":"130,655","shares_owned_after":212014.0,"shares_owned_after_display":"212,014","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-16","filed_date":"2024-05-20","scope":"insider"},{"id":2324834,"accession":"0001610717-24-000205","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001610717-24-000205","line_url":"/filing/0001610717-24-000205#line-2","is_derivative":false,"issuer_cik":"0001628171","issuer_name":"Revolution Medicines, Inc.","issuer_ticker":"RVMD","issuer_name_source":null,"issuer_url":"/issuer/0001628171","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2155.0,"shares_display":"2,155","price_per_share":37.0,"price_display":"37.00","price_state":"stated","total_value":79735.0,"total_display":"79,735.00","total_whole":"79,735","shares_owned_after":15700.0,"shares_owned_after_display":"15,700","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-10","filed_date":"2024-04-12","scope":"insider"},{"id":8357418,"accession":"0001104659-23-071772","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-23-071772","line_url":"/filing/0001104659-23-071772","is_derivative":false,"issuer_cik":"0001737953","issuer_name":"Replimune Group, Inc.","issuer_ticker":"REPL","issuer_name_source":null,"issuer_url":"/issuer/0001737953","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5698.0,"shares_display":"5,698","price_per_share":24.04497542997543,"price_display":"24.04","price_state":"stated","total_value":137008.27,"total_display":"137,008.27","total_whole":"137,008","shares_owned_after":149426.0,"shares_owned_after_display":"149,426","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-13","filed_date":"2023-06-15","scope":"insider","n_lines":2},{"id":8752289,"accession":"0001104659-23-062378","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-062378","line_url":"/filing/0001104659-23-062378#line-1","is_derivative":false,"issuer_cik":"0001737953","issuer_name":"Replimune Group, Inc.","issuer_ticker":"REPL","issuer_name_source":null,"issuer_url":"/issuer/0001737953","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Officer (Chief Strategy Officer)","role_mark":"O","role_mark_label":"Officer (Chief Strategy Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Strategy Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15575.0,"shares_display":"15,575","price_per_share":18.05,"price_display":"18.05","price_state":"stated","total_value":281128.75,"total_display":"281,128.75","total_whole":"281,129","shares_owned_after":154571.0,"shares_owned_after_display":"154,571","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-16","filed_date":"2023-05-18","scope":"insider"},{"id":6397852,"accession":"0001104659-22-062607","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-062607","line_url":"/filing/0001104659-22-062607#line-1","is_derivative":false,"issuer_cik":"0001737953","issuer_name":"Replimune Group, Inc.","issuer_ticker":"REPL","issuer_name_source":null,"issuer_url":"/issuer/0001737953","owner_cik":"0001860609","owner_name":"Patel Sushil","owner_display_name":"Patel Sushil","owner_url":"/insider/0001860609","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10687.0,"shares_display":"10,687","price_per_share":14.59,"price_display":"14.59","price_state":"stated","total_value":155923.33,"total_display":"155,923.33","total_whole":"155,923","shares_owned_after":130146.0,"shares_owned_after_display":"130,146","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-16","filed_date":"2022-05-18","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":22,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":22,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":22},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001737953","name":"Replimune Group, Inc.","url":"/issuer/0001737953","role":"Director, Officer (Chief Executive Officer)","n_filings":9,"first_seen":"2022-05-18","last_seen":"2026-08-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001628171","name":"Revolution Medicines, Inc.","url":"/issuer/0001628171","role":"Director","n_filings":4,"first_seen":"2024-04-12","last_seen":"2026-07-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001860609","retrieved_at":"2026-08-22T17:22:36+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}